In the wake of a study published April 17 in the Journal of the American Medical Association ( JAMA) which reported an increased incidence of gastrointestinal morbidity among men with prostate cancer treated with proton therapy compared with intensity-modulated radiation therapy (IMRT), proton therapy providers have rallied to dispute the findings and study methodology.
Treatment of localized prostate cancer with intensity-modulated radiation therapy (IMRT) may provide improved disease control with less morbidity than conformal radiation therapy, according to an analysis published April 17 in the Journal of the American Medical Association. However, proton therapy did not appear to provide additional benefits for these patients.
Advanced Medical Isotope Corporation (AMIC), a producer and distributor of medical isotopes, has obtained an exclusive license to eight patents for injectable radiogel technology for use in high-dose radiation therapy. The license was granted by Battelle pursuant to an option between Battelle and AMIC announced in February 2011.
The American Registry of Radiologic Technologists (ARRT) has appointed Joey S. Battles, MA Ed, RT, director of educational eligibility requirements.
Researchers at the University of Texas Health Science Center at San Antonio have developed a way to deliver nanoparticle radiation directly to glioblastoma and contain the dose within the tumor, according to a study published March 19 in Neuro-Oncology.
The change in standard uptake value (SUV) max as assessed by 18F-FDG PET/CT before and three months after selective internal radiation therapy (SIRT) was identified as the only independent predictor of survival in patients with hepatic metastases of breast cancer, according to a study published in the February issue of the Journal of Nuclear Medicine.
Radiation therapy departments nationwide are increasingly interfacing their oncology information systems with an EMR with nearly two-thirds of radiation therapy sites having an EMR or complete patient record available in their oncology information systems, according to IMV Medical Information Division.
Four experts attempted to set straight the record on accelerated partial breast brachytherapy (APBI) after a Dec. 7 presentation by MD Anderson researchers at the San Antonio Breast Cancer Symposium, which concluded that APBI is associated with inferior effectiveness and increased toxicity compared with whole breast irradiation in older women. The researchers outlined numerous flaws ranging from the data source to study design to omitted information, during a teleconference on Dec. 13.
89Zr-desferrioxamine B-7E11 displays high tumor-to-background tissue contrast in immuno-PET and can be used as a tool to monitor and quantify with high specificity tumor response in prostate-specific membrane antigen (PSMA)-positive prostate cancer, according to research published in the October issue of the Journal of Nuclear Medicine.
Positive findings at preoperative PET in the mediastinum appear to have prognostic implications for non-small-cell lung cancer despite histologically negative mediastinal lymph nodes, according to a single-center study published in the October issue of Radiology.
The Molecular Imaging Biomarker Research Group of Siemens Medical Solutions USA has completed a Phase II multicenter clinical trial of its HX4 positron PET imaging biomarker, which is designed to detect hypoxia—a reduction in tissue oxygen levels—in solid tumors.
Image-guided thermal ablation of lung malignancies is on the rise and appears to offer a safe choice for a subset of non-surgical candidates. However, additional clinical studies are needed to demonstrate the efficacy of the procedure in comparison with other treatments, according to a review article published in the September issue of Radiology.
Concord Medical Services and GE Healthcare have signed a memorandum of understating (MOU) to form a preferred strategic partnership in China.
National Imaging Associates (NIA) and the American College of Radiation Oncology (ACRO) have signed a collaborative agreement to establish guidelines in radiation therapy treatment.
A combination of well-known safety procedures could prevent most patient-harming errors in radiation therapy, according to a study presented at the annual meeting of the American Association of Physicists in Medicine (AAPM) and Canadian Organization of Medical Physicists, July 31 to Aug. 4 in Vancouver, Canada.
Microscopic gold particles could multiply the effectiveness of standard cancer radiation therapy by acting as tiny missiles that destroy blood vessels feeding cancerous tumors. Early research about this method, which could shorten cancer treatment and make it more effective, is being presented at the 2011 Joint Meeting of the American Association of Physicists in Medicine (AAPM) and Canadian Organization of Medical Physicists (COMP).
The American Society for Radiation Oncology (ASTRO) has announced the results of its recent election. These new officers will begin their terms at the society’s 53rd annual meeting in Miami Beach, Fla., which will be held Oct. 2-6.
Two tiny genetic variations can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment, according to a genome-wide association study (GWAS) published online July 24 in Nature Medicine. Knowing in advance who is at risk could help physicians tailor treatment to reduce the risks for patients who are most susceptible to long-term damage.
After surviving childhood cancer, patients who experience a subsequent neoplasm face a large increase in the risk of developing additional neoplasms, with more than one-quarter developing third or subsequent tumors, and particularly high rates found among those treated for nonmelanoma skin cancers, according to the authors of a large study published June 27 in the Journal of Clinical Oncology.
Cetuximab combined with chemoradiotherapy increases lung cancer survival while inducing side effects comparable to chemotherapy alone, offering promising phase II results that clinicians hope will roll over to an ongoing phase III trial.
|
RSS 
